Precision BioSciences Expands its Presence and Advances Hepatitis Research with New Appointments and Clinical Data
DURHAM, N.C. - Precision BioSciences, an advanced gene editing company utilizing its proprietary ARCUS platform, is making significant strides in the field of gene editing therapies. The company recently announced its addition to the Russell Microcap Index, a prestigious milestone that highlights its growth and potential in the market. This accomplishment follows the conclusion of the 2024 Russell indexes annual reconstitution.
In addition, Precision BioSciences has expanded its Hepatitis Scientific Advisory Board by welcoming two world-class clinical investigators, Mark Sulkowski, M.D. and Jordan Feld, M.D. M.P.H. Dr. Sulkowski and Dr. Feld will join Raymond Schinazi, Ph.D. DSc, as part of the advisory board, contributing their expertise to Precision BioSciences’ PBGENE-HBV program. With their collective knowledge and experience, the company aims to further advance its gene editing therapies for Hepatitis.
Precision BioSciences also presented new preclinical safety data for its PBGENE-HBV clinical candidate at the European Association for the Study of the Liver Congress. The data highlighted the differentiated ability of ARCUS to make efficient, durable, and targeted elimination edits. This exciting development showcases Precision BioSciences’ commitment to developing innovative gene editing therapies.
The inclusion of Precision BioSciences in the Russell Microcap Index serves as a testament to the company’s growth and potential in the gene editing market. The addition of highly esteemed clinical investigators to the Hepatitis Scientific Advisory Board further strengthens Precision BioSciences’ expertise in this specialized area. Additionally, the presentation of preclinical data at a renowned medical conference demonstrates the company’s dedication to advancing the field of gene editing therapies.
In conclusion, Precision BioSciences is making significant strides in the development of gene editing therapies. Through its ARCUS platform and collaborations with world-class clinical investigators, the company is actively expanding its presence in the gene editing market. With its recent achievements and promising preclinical data, Precision BioSciences is solidifying its position as a leader in the field.
Comments